RIGHTMINDER
29.3.2017 08:02:54 CEST | Business Wire | Press release
With the exponential growth of the aged care industry, cost and care issues are prevalent not only in the UK and Europe but globally. ConnectUs Life Pty Ltd, a specialist care-related services provider has launched RightMinder®, an app that leverages advancements in wearable technology and the increase in availability and use of affordable smartwatches. Coinciding with the release of Android Wear 2.0, RightMinder® caters to the elderly, those in need, pre-teens and Professional Carers. Available in multiple languages and in over 136 countries, RightMinder® delivers a patent-pending solution providing fall detection, first alert monitoring and alerts, GPS location reporting, and multiple first alert carer connections.
RightMinder® has been created to connect ‘wearers’ and ‘carers’. Ben Slater, ConnectUs Life CIO says, ”Our core focus is to ensure wearers maintain meaningful independence with an efficient, yet discreet safety and security alert system. Anyone can use RightMinder® without lock-in contracts, nor do they need expensive custom hardware.” Mr Slater says, “Our First Alert Carers are not only from the family & friends orientated network, but also paid professional Carers too.”
Whilst RightMinder® is specifically designed for Android smartwatches (for wearers), the First Alert and Fall Detection functionality is also available on the mobile phone itself, so anyone can use RightMinder® without requiring a smartwatch. However, RightMinder® strongly recommends using a smartwatch for safety and as a discreet alternative to “the big red emergency button” or pendant. Mr Slater says, “We are extremely encouraged by the acceptance of smartwatch technology amongst our focus groups. Wearers have embraced smartwatch technology when paired with the RightMinder® app. RightMinder® has proven to be very easy to use and manage, despite the underlying complexity of the algorithms utilised.”
RightMinder® wearers are securely connected to one or more carers who can then monitor battery life, location and access fast-touch call buttons. If a Wearer triggers a Fall Detection, or if they send an emergency First Alert, their carers all receive immediate notifications and emails to raise an emergency response. Carers then have the option to locate or call their wearers immediately. Additionally when battery life gets low, notifications are also sent to both wearer and carers.
RightMinder® also extends to people living with disabilities such as MS, dementia, brain trauma, epilepsy and for other high need individuals.
RightMinder® helps reduce the level of dependence on professional operators and on tax funded government assistance.
Contrary to the notion that technology can be complicated, RightMinder® is easy-to-use with a user-friendly interface that has been designed to benefit users who are wearers and carers. Alerting carers is now fast, simple and discreet for any RightMinder® wearer.
The convenience that comes with using the app, in addition to the affordability of the innovative concept, gives independence and empowerment to wearers and comfort to carers like never before, even if wearers and carers live countries apart.
RightMinder® aims for peace of mind without being front of mind.
RightMinder® is available on Google Play Store for Carers and Wearers and coming soon to the Apple App Store (for Carers).
For a full video of the app, please see https://www.youtube.com/watch?v=c2XF2YPabDc .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006424/en/
Contact:
RightMinder
Drew Steptoe, Joint MD and CEO.
+61 423 009 082
drew@connectus.life
or
Ben
Slater, Joint MD and CIO.
+61 433 773 585
ben@connectus.life
www.connectus.life
| www.rightminder.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
